Skip to Content

Tagraxofusp use while Breastfeeding

Drugs containing Tagraxofusp: Elzonris

Medically reviewed by Drugs.com. Last updated on Dec 12, 2020.

Tagraxofusp Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of tagraxofusp during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tagraxofusp therapy and for 1 week after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Tagraxofusp

CAS Registry Number

2055491-00-2

Drug Class

  • Breastfeeding
  • Lactation
  • Antineoplastic Agents
  • Recombinant Fusion Proteins

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.